Imerys (HAM:IY4)
€ 21.32 +0.82 (+4%) Market Cap: 1.84 Bil Enterprise Value: 3.24 Bil PE Ratio: 0 PB Ratio: 0.72 GF Score: 53/100

Full Year 2024 Imerys SA Earnings Call Transcript

Feb 21, 2025 / 08:00AM GMT

Key Points

Positve
  • Imerys (IMYSF) achieved a solid performance in 2024 with a 1% organic growth in revenues, reaching EUR3.6 billion.
  • The company posted an adjusted EBITDA of EUR675 million, marking an 11.4% increase over the prior year like-for-like.
  • Imerys generated a free operating cash flow of EUR209 million before strategic CapEx, indicating strong cash generation capabilities.
  • The company continues to offer attractive shareholder remuneration, proposing a 7.4% increase in ordinary cash dividends.
  • Imerys has made strategic acquisitions, such as the European diatomite and perlite business, enhancing its product portfolio in filtration and life sciences.
Negative
  • The automotive market remains a significant concern, with weakness expected to continue, particularly in Europe.
  • The energy sector is weak in Europe and the US, impacting Imerys' performance in these regions.
  • The iron and steel market is under pressure, with recovery delayed until the second half of 2025.
  • Imerys faces challenges in the photovoltaic market due to high inventory levels, particularly in China.
  • There is uncertainty regarding the lithium project's competitiveness without subsidies, given the low-cost brine production in Latin America.
Alessandro Dazza
Imerys SA - Chief Executive Officer, Member of the Executive Committee

Good morning to all of you. Thank you for joining us today to review Imerys Q4 and full year 2024 annual results. With me this morning, Sebastien Rouge, our CFO. Let me start as usual by giving you some highlights for the year we just closed.

In 2024, Imerys delivered a solid performance, posting organic growth and increased EBITDA and increased margin driven by volume recovery. Revenues landed at EUR3.6 billion with a 1% organic growth. In Q4, organic growth amounted to 3.5%, and this was the third consecutive quarter of improvement. This achievement reflects continued volume recovery driven by additional industrial capacities, new product launches, commercial action and pricing turning positive in the second half of the year.

Imerys posted an adjusted EBITDA for the full year at EUR675 million, an 11.4% increase over the prior year like-for-like, and in line with our guidance. Noteworthy, the strong Q4 performance at plus 14% like-for-like compared to 2023. The group generated a free operating

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot